Participants
extrapyramidal signs, schizophrenia, DSM-5, depressive symptoms
DISORDERS, POSITIVE
The study was conducted in 31 adult male and female subjects aged 18 to 60 years, inclusive, with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of schizophrenia, who were receiving stable antipsychotic therapy (no change in dose by >25% in the preceding 2 months). Subjects had a Positive and Negative Symptom Scale (PANSS) negative symptom factor score of at least 15, with minimal fluctuation between screening and baseline (<25% change). This was driven by the fact that negative symptoms were the primary indication being pursued at the time this study was designed. PANSS total score was not to exceed 90 points, with minimal fluctuation between screening and baseline (<20% change). Subjects with extrapyramidal signs or symptoms, or with depressive symptoms, were excluded.